Abstract
No consistently successful therapy has been reported for scleroderma, a chronic disease of unknown cause associated with remissions and relapses. Relaxin therapy has been found to influence to a significant degree certain distressing features of scleroderma and therein represents a therapeutic advance. The degree of improvement noted varied considerably, but several patients were sufficiently benefited to enable return to gainful occupation. Relief of vasospasm, healing of trophic ulceration, and increase in skin elasticity were the most striking results. Other manifestations of the disease were not materially improved by relaxin treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
